Novo subpoenaed by U.S. attorney for manufacturing issues; AbbVie exec scolds Canada over patents;

@FiercePharma: Top-read in FiercePharma Thurs: Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it weekly, subscribe. Subscribe | Follow @CarlyHFierce

> Novo Nordisk ($NVO) reported today that it has been subpoenaed by the U.S. Attorney in Massachusetts over manufacturing issues at a plant in Denmark. Release

> The head of AbbVie's ($ABBV) Canada operations said the country is unlikely to get much R&D investment as long as its patents on drugs is more restrictive than other Western countries. Story

> Jordan's Hikma reports that it has gotten a warning letter from the FDA for a plant in Portugal. Story

Medical Device News

@FierceMedDev: New microscope offers 3D cellular images that are fast, detailed and low toxicity. More | Follow @FierceMedDev

@VarunSaxena2: Bard Q3 earnings up 41% as it focuses on Lutonix launch. Story | Follow @VarunSaxena2

@EmilyWFierce: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

@MichaelGFierce: Encapsulated #Alzheimers, #Parkinsons-treating growth factors implanted directly in the brain. More from FierceDrugDelivery | Follow @MichaelGFierce

> Apple kicks med tech app developers out of the iCloud. Item

> Edwards profit up 23%, but increased TAVR competition looming. Story

Biotech News

@FierceBiotech: $GSK cozies up to Five Prime for respiratory R&D. More | Follow @FierceBiotech

@JohnCFierce: Baxter gets FDA OK for hemophilia A drug -- Obizur. News | Follow @JohnCFierce

@DamianFierce: $AZN's olaparib will trade as Lynparza, which sounds like a nice lady. | Follow @DamianFierce

@EmilyMFierce: Researchers will test blood of Ebola survivors to use as a short-term treatment option. Story | Follow @EmilyMFierce

> AstraZeneca gets some EU encouragement for its $2B cancer hopeful. More

> Shire CFO to exit in wake of failed AbbVie deal. Chutes & Ladders

> NPS Pharma will have to wait another three months for an FDA OK. News

And Finally... Your milk choice may impact your vitamin D levels. More (sub. req.)

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.